Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharma forms new subsidiary in China
Takeda, along with its wholly owned subsidiary, Tianjin Takeda Pharmaceuticals expects to increase its sales force up to approximately 900 in China. The new company will be responsible
Takeda, along with its wholly owned subsidiary, Tianjin Takeda Pharmaceuticals expects to increase its sales force up to approximately 900 in China. The new company will be responsible
The tie up allows Sanofi-aventis to develop a platform for ophthalmology so as to introduce more solutions for patients where unmet therapeutic needs remain, Pharmabiz reported. Under the
Avodart prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. GSK said that it will withdraw applications from regulatory review where procedures are ongoing and, in
The new patent covers the controlled release of drugs and other active compounds, including growth factors that can be incorporated in the wound dressing. The patent entitled ‘Hydrogel
The government has agreed to raise R&D tax credits for small businesses from 175% to 200% from April 2011, and next year to 225%. Proposals to remove the
The company posted a net loss of $8.75m, compared to a net loss of $7.31m for the same period in 2009. Trius’ loss from operations was $9m, as
Norethindrone and Ethinyl Estradiol, USP 0.4 mg/0.035 mg tablets are the generic version of Ovcon 35 tablets by Warner Chilcott. The product will be marketed under the trade
Valacyclovir Hydrochloride Tablets 500mg and 1 gram are the generic equivalent of Valtrex by GlaxoSmithKline. Actavis is a pharmaceutical company specializing in the development, manufacture and sale of
BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches – an innovative class of RNA drug targets found in pathogenic bacteria
As per the agreement, Pozen has licensed Cilag to manufacture, develop and commercialize MT 400 as migraine drug. Pozen previously licensed US-only rights to MT 400 to GlaxoSmithKline,